Company / Cash & Equivalents
Warby Parker Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$286.4M
FY2025
5-year range
$208.6M / $286.4M
FY2021-FY2025
Trend
+12.7%
vs FY2024
Sector context
#67 of 148
Health Care
What the data says
At $286M, Warby Parker Inc.'s cash & equivalents ranks #67 of 148 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $209M in FY2022 to $286M in FY2025.
Based on SEC 10-K filings.
$286M in FY2025 with a 5-year CAGR of -1.8%.
Improved from $217M to $286M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +11.1%
- 5-Year CAGR
- -1.8%
- 10-Year CAGR
- -
Sector benchmark
#67 of 148 in Health CareTop 45% of 148This company $286.4M Sector average $1.2B
▼
-75.7% below sector average
Key checks
Key Insights
- Warby Parker Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of -1.8%, indicating a declining trend.
- In FY2025, cash & equivalents increased 12.7% year-over-year.
- Ranks #67 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $286.4M | +12.7% |
| FY2024 | $254.2M | +17.2% |
| FY2023 | $216.9M | +4.0% |
| FY2022 | $208.6M | -18.7% |
| FY2021 | $256.4M | -18.4% |
| FY2020 | $314.1M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026